note. The Respondent continued to prescribe fentanyl patches for Patient D until near
the end of the treatment period.

56. On May 20, 2013, the Respondent faxed in a prescription for hydrocodone
(Lortab) to an area pharmacy for Patient D. The Respondent did not document this
prescription in an office note, however.

57. On May 29, 2013, the Respondent prescribed hydrocodone and Soma.
On this date, the Respondent ordered UDS that, while positive for hydrocodone and
Soma, was negative for fentanyl. The Respondent did not address this finding in his
progress notes or otherwise address this inconsistency.

58. On June 24, 2013, the Respondent added temazepam to his prescribing
of hydrocodone and Soma. On June 28, 2013, Patient D picked up a prescription for
fentanyl patches from the Respondent's office. The Respondent did not document this
prescription in his progress note.

59. On August 19, 2013, the Respondent documented for the first time
prescribing fentanyl patches in his progress notes.

60. On September 13, 2013, the Respondent ordered UDS that was negative
for fentanyl and Soma, medications the Respondent had prescribed. In his progress
note for this date, the Respondent noted, "no abuse on medication database review."

61. On October 11, 2013, the Respondent noted, "UDT is unremarkable."
The Respondent did not note Patient D's negative UDSs for fentanyl in this note.

62. On December 2, 2013, the Respondent ordered UDS that was negative

for fentanyl and hydrocodone, medications the Respondent had been prescribing on a

13
